SCHEMBL20116736

SCHEMBL20116736

CCOc1ncc(/C(N)=N/O)cc1OC

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 5/20 0.44
MEN1 O00255 1/20 0.44
KMT2A Q03164 1/20 0.44
RECQL P46063 1/20 0.44
NPSR1 Q6W5P4 1/20 0.43
MAPK1 P28482 1/20 0.42
PDE4A P27815 5/20 0.40
PDE4B Q07343 5/20 0.40
PDE4C Q08493 5/20 0.40
PDE4D Q08499 5/20 0.40
BPTF Q12830 1/20 0.40
RAB9A P51151 2/20 0.38
TSHR P16473 2/20 0.37
NCOA1 Q15788 1/20 0.37
NCOA3 Q9Y6Q9 1/20 0.37
HTR2A P28223 1/20 0.36
HTR2C P28335 1/20 0.36
HTR2B P41595 1/20 0.36
NPC1 O15118 1/20 0.35
LMNA P02545 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29040322 0.76 MAPK1 (0.68) GAAMEN1KMT2ARECQLMAPK1
SCHEMBL20116265 0.76 MAPK1 (0.68) GAAMEN1KMT2ARECQLMAPK1
SCHEMBL3463152 0.75 RECQL (0.41) GAAKMT2ARECQLNPSR1RAB9A
SCHEMBL3463153 0.75 RECQL (0.41) GAAKMT2ARECQLNPSR1RAB9A
SCHEMBL29040318 0.73 HDAC1 (0.48) MAPK1TSHRLMNATP53
SCHEMBL20943958 0.73 RECQL (0.44) GAAMEN1KMT2ARECQLNPSR1
SCHEMBL20943959 0.73 RECQL (0.44) GAAMEN1KMT2ARECQLNPSR1
SCHEMBL14832076 0.73 MAPT (0.51) GAAMEN1KMT2AMAPK1PDE4A
SCHEMBL20963460 0.72 RECQL (0.43) GAAMEN1KMT2ARECQLNPSR1
SCHEMBL30744984 0.72 RECQL (0.43) GAAMEN1KMT2ARECQLNPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11873298-B2 Compounds and uses thereof JANSSEN PHARMACEUTICA NV (BE) 2024-01-16 US disclosed
US-11873298-B2 Compounds and uses thereof JANSSEN PHARMACEUTICA NV (BE) 2024-01-16 US disclosed
US-20200262828-A1 COMPOUNDS AND USES THEREOF JANSSEN PHARMACEUTICA NV (BE) 2020-08-20 US disclosed
WO-2019209948-A9 COMPOUNDS AND USES THEREOF YUMANITY THERAPEUTICS, INC. (US) 2020-01-02 WO disclosed
WO-2019018795-A1 COMPOUNDS AND USES THEREOF YUMANITY THERAPEUTICS (US) 2019-01-24 WO disclosed
WO-2018081167-A1 COMPOUNDS AND USES THEREOF YUMANITY THERAPEUTICS (US) 2018-05-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11873298-B2 Compounds and uses thereof NLN, ACHE, CLN6 GAA 67/4885MEN1 1807/4885KMT2A 2479/4885
US-20200262828-A1 COMPOUNDS AND USES THEREOF NLN, ACHE, CLN6 GAA 67/4885MEN1 1807/4885KMT2A 2479/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.